Recently, N’-propylhydrazide analogs of hydroxamic pan-HDAC inhibitors like panobinostat and belinostat have been identified as potent and selective class I HDAC inhibitors with unique anti-cancer properties [23,32,33,34]. Here, HDAC9 is linked to cancer.